Gerry Rhodes

1.4k total citations
21 papers, 709 citations indexed

About

Gerry Rhodes is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Gerry Rhodes has authored 21 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 7 papers in Epidemiology and 5 papers in Virology. Recurrent topics in Gerry Rhodes's work include HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Gerry Rhodes is often cited by papers focused on HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Gerry Rhodes collaborates with scholars based in United States and South Korea. Gerry Rhodes's co-authors include Adrian S. Ray, Jennifer E. Vela, L. Tong, Tomáš Cihlář, Eugene Eisenberg, Michael D. Fuller, Bernard P. Murray, Lianhong Xu, Kirsten M. Stray and Luong Tsai and has published in prestigious journals such as Journal of Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and Journal of Hepatology.

In The Last Decade

Gerry Rhodes

21 papers receiving 688 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Gerry Rhodes 434 273 145 106 100 21 709
J. J. PLATTNER 406 0.9× 293 1.1× 73 0.5× 159 1.5× 48 0.5× 25 722
Mary Beth Wire 325 0.7× 170 0.6× 289 2.0× 83 0.8× 70 0.7× 36 957
Katy H. P. Moore 745 1.7× 393 1.4× 305 2.1× 117 1.1× 123 1.2× 24 1.1k
L. Tong 529 1.2× 261 1.0× 123 0.8× 54 0.5× 142 1.4× 10 648
Paul Savina 525 1.2× 292 1.1× 141 1.0× 184 1.7× 68 0.7× 22 742
Jean‐Pierre Sommadossi 409 0.9× 227 0.8× 113 0.8× 119 1.1× 52 0.5× 18 558
Xiao‐Jian Zhou 475 1.1× 215 0.8× 318 2.2× 213 2.0× 57 0.6× 44 1.0k
Neil Buss 375 0.9× 252 0.9× 130 0.9× 98 0.9× 71 0.7× 17 655
Jennifer E. Vela 931 2.1× 367 1.3× 296 2.0× 317 3.0× 122 1.2× 19 1.2k
Gregory E. Chittick 484 1.1× 287 1.1× 198 1.4× 78 0.7× 90 0.9× 18 798

Countries citing papers authored by Gerry Rhodes

Since Specialization
Citations

This map shows the geographic impact of Gerry Rhodes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerry Rhodes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerry Rhodes more than expected).

Fields of papers citing papers by Gerry Rhodes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerry Rhodes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerry Rhodes. The network helps show where Gerry Rhodes may publish in the future.

Co-authorship network of co-authors of Gerry Rhodes

This figure shows the co-authorship network connecting the top 25 collaborators of Gerry Rhodes. A scholar is included among the top collaborators of Gerry Rhodes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerry Rhodes. Gerry Rhodes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yang, Huiling, Yujin Wang, Gerry Rhodes, et al.. (2016). Preclinical Characterization of the Novel HCV NS3 Protease Inhibitor GS-9256. Antiviral Therapy. 22(5). 413–420. 4 indexed citations
3.
Liu, H, Lianhong Xu, Hon C. Hui, et al.. (2013). Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region. Bioorganic & Medicinal Chemistry Letters. 24(3). 989–994. 9 indexed citations
4.
Xu, Lianhong, Allen Y. Hong, Bernard P. Murray, et al.. (2013). Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350). Bioorganic & Medicinal Chemistry Letters. 24(3). 995–999. 22 indexed citations
5.
Yang, Hai, Cheng Yong Yang, Gerry Rhodes, et al.. (2011). 779 PRECLINICAL CHARACTERIZATION OF THE NOVEL HCV NS3 PROTEASE INHIBITOR GS-9256. Journal of Hepatology. 54. S313–S313. 2 indexed citations
6.
Zheng, Xiaobo, Bing Lu, Gerry Rhodes, et al.. (2011). 1129 PRECLINICAL CHARACTERIZATION OF GS-9620, A POTENT AND SELECTIVE ORAL TLR7 AGONIST. Journal of Hepatology. 54. S446–S447. 6 indexed citations
7.
Corsa, Amoreena C., Margaret Robinson, Hai Yang, et al.. (2011). 778 PRECLINICAL PROPERTIES OF THE NOVEL HCV NS3 PROTEASE INHIBITOR GS-9451. Journal of Hepatology. 54. S313–S313. 4 indexed citations
8.
Mo, Hongmei, Chi-Cheng Yang, Mingjun Huang, et al.. (2010). Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors. Journal of Viral Hepatitis. 18(5). 338–348. 11 indexed citations
9.
LaPorte, Matthew G., Charles W. Blackledge, Lara K. Leister, et al.. (2010). The discovery and structure–activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase. Bioorganic & Medicinal Chemistry Letters. 20(9). 2968–2973. 33 indexed citations
10.
Mitchell, Michael L., Jong Chan Son, Hongyan Guo, et al.. (2010). N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic & Medicinal Chemistry Letters. 20(5). 1589–1592. 12 indexed citations
11.
Xu, Lianhong, Hongtao Liu, Bernard P. Murray, et al.. (2010). Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer. ACS Medicinal Chemistry Letters. 1(5). 209–213. 152 indexed citations
12.
Rompay, Koen K. A. Van, et al.. (2009). Nucleotide Analogue Prodrug Tenofovir Disoproxil Enhances Lymphoid Cell Loading following Oral Administration in Monkeys. Molecular Pharmaceutics. 6(4). 1145–1151. 51 indexed citations
13.
Ray, Adrian S., Tomáš Cihlář, L. Tong, et al.. (2006). Mechanism of Active Renal Tubular Efflux of Tenofovir. Antimicrobial Agents and Chemotherapy. 50(10). 3297–3304. 269 indexed citations
14.
Joseph, D., Anne N. Nafziger, Gerry Rhodes, Siyu Liu, & Joseph Bertino. (2006). DURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAM. Drug Metabolism and Disposition. 34(5). 783–785. 18 indexed citations
15.
Joseph, D., et al.. (2006). The Effect of Oral Pleconaril on Hepatic Cytochrome P450 3A Activity in Healthy Adults Using Intravenous Midazolam as a Probe. The Journal of Clinical Pharmacology. 46(1). 103–108. 17 indexed citations
16.
Rhodes, Gerry, et al.. (2003). Synthesis of novel polymeric colorants. Coloration Technology. 119(1). 48–56. 1 indexed citations
17.
Davis, Charles B., Deborah Kwok, T K Hart, et al.. (1995). Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.. Drug Metabolism and Disposition. 23(10). 1028–1036. 26 indexed citations
18.
Davis, Charles B., et al.. (1994). Disposition of growth hormone-releasing peptide (SK&F 110679) in rat and dog following intravenous or subcutaneous administration.. Drug Metabolism and Disposition. 22(1). 90–98. 2 indexed citations
19.
Davis, Charles B., et al.. (1994). Disposition of growth hormone-releasing peptide (SK&F 110679) in rat and dog following intravenous or subcutaneous administration.. PubMed. 22(1). 90–8. 8 indexed citations
20.
Nichols, Andrew J., et al.. (1994). The in vivo pharmacological profile of the novel glycoprotein IIb/IIIa antagonist, SK&F 106760.. PubMed. 270(2). 614–21. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. J. PLATTNER Breakdown of academic impact, for papers by Mary Beth Wire Breakdown of academic impact, for papers by Katy H. P. Moore Breakdown of academic impact, for papers by L. Tong Breakdown of academic impact, for papers by Paul Savina Breakdown of academic impact, for papers by Jean‐Pierre Sommadossi Breakdown of academic impact, for papers by Xiao‐Jian Zhou Breakdown of academic impact, for papers by Neil Buss Breakdown of academic impact, for papers by Jennifer E. Vela Breakdown of academic impact, for papers by Gregory E. Chittick
Rankless by CCL
2026